FDA Determines Regulatory Review Period for IVY BLOCK Patent Extension

Summary

The Food and Drug Administration has officially confirmed the regulatory review period for IVY BLOCK, a human drug product, in response to a patent extension application submitted to the US Patent and Trademark Office.